Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer
Status:
Active, not recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to establish the safety and tolerability of pembrolizumab when
administered in combination with either of two chemotherapy regimens (weekly paclitaxel or
capecitabine) in unresectable/metastatic triple negative breast cancer (MTNBC) patients.